CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors, represented by programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors, target the regulatory pathway of T cells to enhance antitumor immunity, and these agents showed durable clinical benefits and long-term remissions in some advanced NSCLC patients (15–17).